Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11001 - 11025 of 12884 in total
QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (RHO) gene.
Investigational
AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Investigational
Investigational
Investigational
Investigational
Investigational
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Investigational
ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.
Investigational
Investigational
Investigational
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
Investigational
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
Investigational
Investigational
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
Displaying drugs 11001 - 11025 of 12884 in total